SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases & Vaccines
- Oncology & Hematology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI®
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Global Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Meet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREIQVIA Careers
Featured Careers
Stay Connected
WE'RE HIRING
"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESWhite Paper
Antibody-Drug Conjugates in Cancer Therapy
IQVIA Ark Patent Intelligence
Sep 16, 2025
Cancer remains one of the most formidable health challenges, affecting millions of lives across every corner of the globe. The World Health Organisation's 2024 report recorded 20 million new cancer cases and 9.7 million deaths in 2022, with projections reaching 35 million cases by 2050.2 Conventional cancer treatment options were quite systemic and non-specific, leading to side effects. Over decades, a remarkable shift towards more targeted and personalized therapies have led to the use of antibody-drug conjugates (ADCs) as a promising therapy for cancer.
ADCs are advanced therapies that link monoclonal antibodies (mAbs) to potent cytotoxic drugs, known as payloads, via cleavable or non-cleavable linkers. They deliver drugs directly to cancer cells by recognizing specific antigens, thereby minimizing harm to healthy tissue, and enabling a bystander effect that kills nearby tumour cells. Despite their promise, ADCs are complex and costly to develop, with challenges, including off-target toxicity and drug resistance. Currently, 15 ADCs are approved for various cancers, such as breast, blood, gastric, urothelial, cervical, and lung cancers, and around 200 are in clinical trials, including 24 in Phase III, all driven by advances in antibody, linker, and payload technologies.
Today, ADCs have proven to be game changers in cancer therapy with growing market needs. The first ADC drug approval, Pfizer's MylotargTM (Gemtuzumab ozogamicin) by the US Food and Drug Administration (FDA) in 2000 for treating acute myeloid leukaemia (AML), marked a milestone in precision oncology. The European Medicines Agency (EMA) followed with approval in 2018, granting it orphan drug status due to the rarity of AML. The USA ADC market, valued at USD 11.3 billion in 2023, is projected to grow rapidly in the upcoming years.
Ark Patent Intelligence offers comprehensive insights into the global ADC drug market. It provides extensive worldwide information on drug approvals, market insights, key patents, regulatory protections, litigation trends, and detailed in-depth analyses of marketed, registered and phase III drugs covering more than 30 ADCs.
Explore how ADCs are transforming cancer therapy and reshaping market dynamics. Read this white paper for insights on patent strategy, biosimilar timelines, and innovation opportunities in oncology.
You may also be interested in
Institute Report
Oncology Therapy Access in the Era of Personalized Medicine
Trends in regulatory approval and reimbursement for select countries in the Middle East and Africa
White Paper
Achieving Oncology Launch Excellence
How to navigate harsh realities in a highly fluid environment